US 12,109,257 B2
Alphavirus neoantigen vectors
Wade Blair, Gaithersburg, MD (US); Karin Jooss, Emeryville, CA (US); Amy Rachel Rappaport, Daly City, CA (US); Ciaran Daniel Scallan, San Francisco, CA (US); and Leonid Gitlin, Foster City, CA (US)
Assigned to Gritstone Bio, Inc., Emeryville, CA (US)
Filed by Gritstone bio, Inc., Emeryville, CA (US)
Filed on Oct. 11, 2022, as Appl. No. 18/045,812.
Application 18/045,812 is a division of application No. 16/612,352, granted, now 11,504,421, previously published as PCT/US2018/031696, filed on May 8, 2018.
Claims priority of provisional application 62/590,163, filed on Nov. 22, 2017.
Claims priority of provisional application 62/523,201, filed on Jun. 21, 2017.
Claims priority of provisional application 62/503,283, filed on May 8, 2017.
Prior Publication US 2024/0024445 A1, Jan. 25, 2024
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61P 31/12 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/001191 (2018.08) [A61K 39/001188 (2018.08); A61K 39/12 (2013.01); A61P 31/12 (2018.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); C12N 15/86 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/605 (2013.01); A61K 2039/70 (2013.01)] 20 Claims
 
1. A method for inducing an immune response in a subject, comprising:
(A) administering a first vaccine composition, wherein the first vaccine composition comprises a chimpanzee adenovirus vector comprising a first neoantigen cassette; and
(B) administering a second vaccine composition comprising an neoantigen expression system, wherein the neoantigen expression system comprises one or more vectors, wherein the one or more vectors each comprise:
(a) an RNA alphavirus backbone, wherein the RNA alphavirus backbone comprises:
(i) at least one promoter nucleotide sequence, and
(ii) at least one polyadenylation (poly(A)) sequence; and
(b) a second neoantigen cassette; and
wherein the first neoantigen cassette and the second neoantigen cassette comprise
at least one neoantigene-encoding nucleic acid sequence that is the same.